Graduate School of Pharmaceutical Sciences, Tohoku University.
Departments of Pharmaceutical Sciences.
Ther Drug Monit. 2019 Oct;41(5):615-619. doi: 10.1097/FTD.0000000000000649.
Sirolimus and tacrolimus require accurate drug dosing based on their target blood levels to produce better clinical outcomes, specifically, the avoidance of drug-induced adverse effects and the maintenance of efficacy. However, because the ideal dose of sirolimus and the schedule for measuring its blood levels are unclear in lung transplant patients, an index is required for estimating sirolimus blood concentrations. The aim of this work is to study the correlation between the trough concentration/dose normalized by body weight (C0/D) ratios of sirolimus and tacrolimus in lung transplant patients.
Thirteen lymphangiomyomatosis patients who underwent lung transplantation and were treated with sirolimus and tacrolimus from February 2015 to July 2018 were divided into 2 groups, one receiving twice-daily (TD, n = 6) and the other once-daily (OD, n = 7) tacrolimus formulations. The correlation between the C0/D ratio of sirolimus and patient background was evaluated using Spearman's rank correlation coefficient. Correlations between sirolimus and tacrolimus C0/D ratios or doses were analyzed by single regression analysis.
Significant correlations were found between the C0/D ratios of sirolimus and tacrolimus. The regression equations from the initial data of TD and OD groups at steady state were y = 1.880x + 32.636 (adjusted R = 0.743, P = 0.017) and y = 1.684x + 38.816 (adjusted R = 0.919, P < 0.001), respectively. In addition, the regression equations from all data of TD and OD groups were y = 1.883x + 4.170 (adjusted R = 0.546, P < 0.001) and y = 1.950x + 43.188 (adjusted R = 0.898, P < 0.001), respectively. A significant correlation between the dosage of sirolimus and tacrolimus was observed only in the OD group, with relatively low accuracy.
Blood sirolimus concentrations can be estimated using the C0/D ratio of tacrolimus, suggesting that the C0/D ratio of tacrolimus is an index of required sirolimus dosage and the frequency of blood sirolimus concentration measurements.
西罗莫司和他克莫司需要根据其目标血药浓度进行准确的药物剂量调整,以产生更好的临床效果,具体来说,避免药物引起的不良反应和维持疗效。然而,由于肺移植患者中西罗莫司的理想剂量和测量其血药浓度的时间表尚不清楚,因此需要一个指标来估计西罗莫司的血药浓度。本研究旨在探讨肺移植患者中西罗莫司和他克莫司谷浓度/剂量与体重比值(C0/D)之间的相关性。
2015 年 2 月至 2018 年 7 月,我们对 13 例淋巴管平滑肌瘤病患者进行了肺移植,并接受西罗莫司和他克莫司治疗。根据他克莫司的用药方案,将患者分为 2 组,每日 2 次(TD,n=6)和每日 1 次(OD,n=7)。采用 Spearman 秩相关系数评估西罗莫司 C0/D 比值与患者背景的相关性。采用单回归分析分析西罗莫司与他克莫司 C0/D 比值或剂量的相关性。
西罗莫司和他克莫司的 C0/D 比值之间存在显著相关性。TD 和 OD 组稳定状态下的初始数据回归方程分别为 y=1.880x+32.636(调整 R=0.743,P=0.017)和 y=1.684x+38.816(调整 R=0.919,P<0.001)。此外,TD 和 OD 组所有数据的回归方程分别为 y=1.883x+4.170(调整 R=0.546,P<0.001)和 y=1.950x+43.188(调整 R=0.898,P<0.001)。仅在 OD 组中观察到西罗莫司剂量与他克莫司之间存在显著相关性,但准确性相对较低。
可以使用他克莫司的 C0/D 比值来估算西罗莫司的血药浓度,这表明他克莫司的 C0/D 比值是西罗莫司所需剂量和西罗莫司血药浓度测量频率的指标。